MA34961B1 - Inhibiteurs de la cathepsine c - Google Patents

Inhibiteurs de la cathepsine c

Info

Publication number
MA34961B1
MA34961B1 MA36229A MA36229A MA34961B1 MA 34961 B1 MA34961 B1 MA 34961B1 MA 36229 A MA36229 A MA 36229A MA 36229 A MA36229 A MA 36229A MA 34961 B1 MA34961 B1 MA 34961B1
Authority
MA
Morocco
Prior art keywords
cathepsin
inhibitors
disease
butenamides
amino
Prior art date
Application number
MA36229A
Other languages
English (en)
Inventor
Christopher E Neipp
Michael R Palovich
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46638952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34961(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA34961B1 publication Critical patent/MA34961B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des 4-amino-2-butenamides de formule (I) ayant une activité pharmacologique, des compositions pharmaceutiques en contenant et des méthodes de traitment de maladies à médiation par l'enzyme qu'est la cathepsine C, notamment la maladie pulmonaire obstructive chronique.
MA36229A 2011-02-11 2012-02-09 Inhibiteurs de la cathepsine c MA34961B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161441840P 2011-02-11 2011-02-11
PCT/US2012/024428 WO2012109415A1 (fr) 2011-02-11 2012-02-09 Inhibiteurs de la cathepsine c

Publications (1)

Publication Number Publication Date
MA34961B1 true MA34961B1 (fr) 2014-03-01

Family

ID=46638952

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36229A MA34961B1 (fr) 2011-02-11 2012-02-09 Inhibiteurs de la cathepsine c

Country Status (24)

Country Link
US (2) US8841463B2 (fr)
EP (1) EP2672821B9 (fr)
JP (1) JP5931929B2 (fr)
KR (1) KR20140048857A (fr)
CN (1) CN103491777B (fr)
AR (1) AR085163A1 (fr)
AU (1) AU2012214405B2 (fr)
BR (1) BR112013020510A2 (fr)
CA (1) CA2827157A1 (fr)
CL (1) CL2013002325A1 (fr)
CO (1) CO6741219A2 (fr)
DO (1) DOP2013000182A (fr)
EA (1) EA023168B1 (fr)
ES (1) ES2583091T3 (fr)
IL (1) IL227814A0 (fr)
MA (1) MA34961B1 (fr)
MX (1) MX2013009279A (fr)
PE (1) PE20140999A1 (fr)
PH (1) PH12013501665A1 (fr)
SG (1) SG192669A1 (fr)
TW (1) TW201302736A (fr)
UY (1) UY33905A (fr)
WO (1) WO2012109415A1 (fr)
ZA (1) ZA201306074B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014091443A1 (fr) 2012-12-13 2014-06-19 Glaxo Group Limited Inhibiteurs de la cathepsine c pour traiter la mucoviscidose, la bronchectasie sans fibrose kystique, et la vascularite associée aux anca
NO2699580T3 (fr) 2014-01-24 2018-02-24
CN109153642B (zh) * 2016-02-12 2022-05-17 法玛西斯有限公司 赖氨酰氧化酶的吲哚及氮杂吲哚卤化烯丙胺衍生物抑制剂及其用途
IL317570A (en) 2022-06-13 2025-02-01 Alivexis Inc Azacycloalkylcarbonyl cyclic amines and their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2622581B1 (fr) * 1987-11-03 1990-02-16 Inorgan Sa Rech Develop Pharm Nouveaux derives de l-proline, leur preparation et leurs applications biologiques
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
CN1240355A (zh) * 1996-05-01 2000-01-05 伊莱利利公司 蛋白激酶c抑制剂增强溶癌剂和放射治疗的临床功效的用途
US6214799B1 (en) 1996-05-14 2001-04-10 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
AU2002232558A1 (en) * 2000-12-12 2002-06-24 Corvas International, Inc. Compounds, compositions and methods for treatment of parasitic infections
CA2683695C (fr) 2007-04-12 2013-06-18 Pfizer Inc. Nouveaux derives de 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h.6h) carbaldehyde
AU2010244218B2 (en) * 2009-05-07 2012-07-19 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
UY32827A (es) * 2009-08-12 2011-02-28 Glaxo Group Ltd Inhibidores de catepsina c
WO2012119941A1 (fr) 2011-03-04 2012-09-13 Prozymex A/S Composés de peptidylnitrile à titre d'inhibiteurs de peptidases

Also Published As

Publication number Publication date
AU2012214405B2 (en) 2015-07-23
JP5931929B2 (ja) 2016-06-08
CN103491777A (zh) 2014-01-01
SG192669A1 (en) 2013-09-30
EA201391155A1 (ru) 2014-01-30
EP2672821B9 (fr) 2016-11-23
KR20140048857A (ko) 2014-04-24
JP2014506577A (ja) 2014-03-17
AR085163A1 (es) 2013-09-11
DOP2013000182A (es) 2014-03-16
CL2013002325A1 (es) 2014-01-03
US20140364476A1 (en) 2014-12-11
EP2672821A4 (fr) 2014-08-06
ES2583091T3 (es) 2016-09-19
IL227814A0 (en) 2013-09-30
BR112013020510A2 (pt) 2016-07-12
CO6741219A2 (es) 2013-08-30
US8841463B2 (en) 2014-09-23
UY33905A (es) 2012-08-31
PE20140999A1 (es) 2014-09-11
CA2827157A1 (fr) 2012-08-16
US9187461B2 (en) 2015-11-17
MX2013009279A (es) 2013-10-28
WO2012109415A1 (fr) 2012-08-16
EP2672821B1 (fr) 2016-04-20
EA023168B1 (ru) 2016-04-29
US20130324584A1 (en) 2013-12-05
AU2012214405A1 (en) 2013-04-18
EP2672821A1 (fr) 2013-12-18
NZ614540A (en) 2015-03-27
PH12013501665A1 (en) 2019-07-17
TW201302736A (zh) 2013-01-16
ZA201306074B (en) 2014-04-30
CN103491777B (zh) 2015-05-06

Similar Documents

Publication Publication Date Title
EA201490696A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантной idh
BR112013032720A2 (pt) "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados"
EA201201161A1 (ru) Пирролопиримидины в качестве ингибиторов cdk4/6
UA103272C2 (uk) 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
EA201390579A1 (ru) Производные хиназолин-4(3h)-она, используемые как ингибиторы pi3-киназы
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
MA35285B1 (fr) Indazoles
EA201500278A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
EA201301353A1 (ru) Композиции и способы получения пиримидиновых и пиридиновых соединений с втк ингибирующей активностью
EA201301019A1 (ru) Бензодиоксановые ингибиторы продуцирования лейкотриена
EA201270575A1 (ru) Соединения
MA35114B1 (fr) 1,3-oxazines à titre d'inhibiteurs de bace1 et/ou de bace2
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
EP2257161A4 (fr) Inhibiteurs de l'ahcy hydrolase destinés au traitement de l'hyper-homocystéinémie
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
MA44948A1 (fr) Inhibiteurs de bace 1
GEAP201813860A (en) Novel compounds
CA2878796C (fr) Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
EA201291055A1 (ru) Ингибиторы протеинтирозинкиназной активности и их применение для лечения глазных заболеваний